PAI-1 antagonists: Predictable indications and unconventional applications

Douglas E. Vaughan*, Bart M. De Taeye, Mesut Eren

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

37 Scopus citations


At present, thrombolytic agents represent the only direct way of augmenting fibrinolytic activity in humans. While these agents are proven to be efficacious in the treatment of acute thrombotic events, they are not a viable option for long-term administration. There are numerous drugs available that indirectly to increase fibrinolytic activity by reducing plasma levels of plasminogen activator inhibitor-1 (PAI-1), including ACE inhibitors, insulin-sensitizing agents, and hormone replacement therapy in women. At present, efforts are underway to develop and test synthetic, selective PAI-1 antagonists. The potential applications of PAI-1 antagonists include thrombotic disorders (arterial and venous), amyloidosis, obesity, polycystic ovarian syndrome, and perhaps even type 2 diabetes mellitus. The availability of specific PAI-1 antagonists promises to expand the limits of understanding the role the fibrinolytic system plays in human disease and break through the current confines of therapeutic options that can effectively restore and augment the activity of the fibrinolytic system.

Original languageEnglish (US)
Pages (from-to)962-970
Number of pages9
JournalCurrent Drug Targets
Issue number9
StatePublished - Sep 2007


  • Arteriosclerosis
  • Fibrinolysis
  • Plasminogen activator inhibitor-1 (PAI-1)
  • Thrombosis

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry


Dive into the research topics of 'PAI-1 antagonists: Predictable indications and unconventional applications'. Together they form a unique fingerprint.

Cite this